Aim: To investigate an association between autoimmune disorders (AID) and hospitalization for dementia and Alzheimer's disease, and to study whether the risk is associated with followup time and age.
Introduction
Alzheimer's disease is the most common cause of dementia in older adults, accounting for 60-70% of all dementia. The prevalence in people aged >65 years is 6.4% for dementia and 4.4% for Alzheimer's disease. 1 The discoveries of amyloid β (Aβ) and tau, which are the principal components of plaques and tangles, respectively, have resulted in detailed information about molecular pathogenetic events in Alzheimer's disease, reviewed by Scheltens et al. 2 Still, little is known about the exact cause of Alzheimer's disease, and no curative treatments are available. Even for vascular dementia, controversy over the exact nature of the relationship between cerebrovascular pathology and cognitive impairment exists. 3 Evidence from epidemiological, neuroimaging and neuropathological research supports the role of educational level, genetic, vascular and psychosocial factors in the development of Alzheimer's disease. [4] [5] [6] [7] [8] [9] [10] Genetic susceptibility has been proven to play a role in the development of Alzheimer's disease. Early-onset familial Alzheimer's disease is often caused by autosomal dominant mutations, which account for approximately just 2-5% of all patients with Alzheimer's disease. 11 Autoimmune diseases (AID) are a heterogeneous group of 70-80 specific disorders affecting approximately 3-8% of the population in the USA. 12 The association between Alzheimer's disease and AID has been examined in several previous studies; for example, type 1 diabetes, 13 autoimmune thyroid disease, 14 systemic lupus erythematosus 15 and rheumatoid arthritis 16 have been associated with Alzheimer's disease. Alzheimer's disease has also been considered as an AID in a study that suggested autoimmunityinduced cell death in Alzheimer's disease. 15 Previous studies of the association between dementia and Alzheimer's disease and AID have often been small and carried out mostly in individual AID. We postulated that the inflammation associated with AID could affect the risk of dementia and Alzheimer's disease in 42 AID. Using the Swedish National Patient Register (SNPR), we evaluated the risk of a diagnosis of dementia and Alzheimer's disease in all patients previously diagnosed with an autoimmune disorder in Sweden without a previous diagnosis of dementia and Alzheimer's disease.
Methods
Data used in the present study were retrieved from the nationwide database, located at the Center for Primary Health Care Research, Lund University, Malmö, Sweden. The database is a single, comprehensive resource that contains individual-level information on all people in Sweden, including age, sex, socioeconomic status, occupation, geographical region of residence, hospital diagnoses and dates of hospital admissions in Sweden (1964-2010), date of emigration, and date and cause of death. This unique database was constructed using several national Swedish data registers, including, but not limited to, the total population register, the multigeneration register and SNPR . Patients registered for hospitalization stayed in hospital at least one night, usually in wards with specialists. The register also includes outpatients from 2001. Primary care is not included, only specialist care. Diagnoses were reported according to the different versions of the International Classification of Diseases (ICD), classified in 42 autoimmune conditions of diseases (Table S1 ). All linkages were carried out using the national 10-digit civic registration number assigned to each person in Sweden for his or her lifetime. This number was replaced by serial numbers to ensure the anonymity of all individuals.
Outcome variable
We used the main diagnoses for autoimmune disorders recorded in the SNPR. In the present study, the last diagnosis for AID was defined as the case according to one of three codes from the ICD (7th, 8th, 9th and 10th revisions) that appeared in the SNPR during the study period. 
Individual variables controlled for in the analysis
Sex: men and women.
Age at diagnosis was categorized in 5-year groups. Socioeconomic status was divided into five categories: (i) unskilled/skilled workers; (ii) white-collar workers; (iii) professionals; (iv) farmers; and (v) self-employed.
Region of residence was divided into: (i) large cities (cities with a population of >200 000, i.e. Stockholm, Gothenburg and Malmö); (ii) Southern Sweden; and (iii) Northern Sweden. Geographical region was included as an individual variable to adjust for possible differences between geographical regions in Sweden regarding hospital admissions for Alzheimer's disease.
Comorbidity 
Statistical analysis
Person-years were calculated from start of follow up on 1 January 1964 until diagnosis of the last autoimmune disorder in SNPR, death, emigration or closing date (31 December 2010), whichever came first. Standardized incidence ratios (SIR) were calculated as the ratio of observed to expected number of cases. The expected number of cases was calculated for age (5-year groups), sex, period (5-year groups), region and socioeconomic status-specific standard incidence rates. The 95% confidence intervals (95% CI) were calculated assuming a Poisson distribution. 17 The follow-up time was divided according to the time after the diagnosis of AID, namely <1, 1-4, 5-9 and >9 years, allowing the assessment of the effect of follow-up time. AID with <10 cases of dementia and Alzheimer's disease are not shown in the results (i.e. angiitis hypertensive disease, Behçet's disease, chorea minor, Takayasu's disease and thrombotic thrombocytopenic purpura).
Ethical considerations
The ethics committee at Lund University, Malmö, Sweden, approved this study.
Results
The database covered the years 1964-2010 in the SNPR and included 788 103 cases of 42 conditions of AID (Table S1) , with the mean age at diagnosis of 55.6 years. The largest diagnostic groups were: type 1 diabetes 122 684, psoriasis 108 607 and rheumatoid arthritis 106 941 patients. These three groups accounted for >42% of all cases. Table 1 shows the total number of dementia and Alzheimer's disease cases in the entire population (14 411 278 individuals). A total of 236 278 cases of dementia and Alzheimer's disease were diagnosed between 1964 and 2010, with a mean age at diagnosis of 78.7 years. A total of 80% of cases diagnosed were in patients aged between 70 and 78 years. The comorbidities (defined as main or second hospital diagnosis) adjusted for are presented in Table 1 .
During the study period, a total of 9998 patients developed dementia and Alzheimer's disease after being diagnosed for AID, following their last record for AID ( Table 2) . The results are shown when at least 10 cases were observed. The overall SIR was 1.28 (95% CI 1.26-1.31). The data were analyzed according to the subtypes of Alzheimer's disease and dementia. The overall SIR was 1.20 (95% CI 1.15-1.25) for Alzheimer's disease after AID, 1.37 (95% CI 1.31-1.43) for vascular dementia and 1.29 (95% CI 1.26-1.32) for others. AID in patients who likely had an increased risk for both vascular dementia and Alzheimer's disease included Hashimoto's thyroiditis, type 1 diabetes mellitus, giant-cell arteritis and polymyalgia rheumatica. Pernicious anemia, Sjögren's syndrome, Graves' disease and sarcoidosis showed an increased risk for Alzheimer's disease, whereas multiple sclerosis showed a low SIR for Alzheimer's disease. celiac disease, chronic rheumatic heart disease, chronic glomerulonephritis, psoriasis, rheumatoid arthritis and Wegener granulomatosis showed an increased risk for vascular dementia.
Follow-up time of dementia, Alzheimer's disease and AID Data were analyzed according to the follow up of dementia and Alzheimer's disease after AID. The risks were decreased with follow-up time (Table S2) . AID with increased SIR for dementia and Alzheimer's disease in the whole period were the following: celiac disease, chronic rheumatic heart disease, Crohn's disease, giant-cell arteritis, chronic glomerulonephritis, Graves' disease, pemphigus, pernicious anemia, polymyalgia rheumatica, psoriasis, rheumatoid arthritis, sarcoidosis and ulcerative colitis.
The overall SIR of 1.28 and SIR of 1.23 for dementia and Alzheimer's disease were diagnosed after 1 year of hospitalization (1+; Table S3 ). As the risks were very high for some cases of dementia and Alzheimer's disease during the first year, data for 1+ for the whole period is shown separately. Of the 42 studied AID, 17 showed an increased risk. The remaining 14 conditions were still at risk, when dementia and Alzheimer's disease diagnosed in the year of AID diagnosis were excluded. The high risks are probably because of a concomitant diagnosis of dementia, Alzheimer's Autoimmune disorders and dementia © 2018 Japan Geriatrics Society | 1351 disease and AID. However, significant increases in SIR were correlated for the whole and 1+ periods for dementia and Alzheimer's disease. The highest overall increase of 1.66 was noted for Hashimoto's thyroiditis/hypothyroidism, Addison's disease (1.64), pernicious anemia (1.64), type 1 diabetes (1.61) and Sjögren's syndrome (1.48).
Sex and age at diagnosis of dementia, Alzheimer's disease and AID
The overall SIR of dementia and Alzheimer's disease after AID was similar in men (1.32) and women (1.26; Table S3 ). The AIDspecific SIR also did not show any significant sex differences. Data were analyzed according to the age at diagnosis of dementia and Alzheimer's disease (Table S4 ). For all conditions of patients with AID, a higher risk of dementia and Alzheimer's disease was observed for those hospitalized at a younger age. Most of the patients with dementia and Alzheimer's disease had been diagnosed at older ages (age ≥70 years), which is in line with the age distribution for dementia and Alzheimer's disease. However, in general, increased risk of dementia and Alzheimer's disease for those diagnosed before the age of 60 years (overall SIR 2.29) was significantly higher than that in those diagnosed at older ages. Patients diagnosed for AID likely experienced an increased risk of dementia and Alzheimer's disease before the age of 60 years. These conditions included: ankylosing spondylitis, chronic rheumatic heart disease, Crohn's disease, type 1diabetes, Graves' disease, Hashimoto's thyroiditis, multiple sclerosis, pernicious anemia and systemic lupus erythematosus. Low SIR for dementia and Alzheimer's disease in those hospitalized at ages >80 years were shown for lupoid hepatitis, multiple sclerosis and rheumatoid arthritis.
Discussion
The main finding of the present follow-up study is the strong association between dementia and Alzheimer's disease, and many conditions of AID after accounting for age, sex, socioeconomic status, period and geographic region. The risk of dementia and Alzheimer's disease was influenced by the age at hospitalization, but whether the age effect increased or decreased depended on the AID conditions.
Our data gave us the opportunity to carry out a large-scale follow-up study of the association between 42 subtypes of AID, and dementia and Alzheimer's disease. In addition, the availability of hospital data in the entire population eliminated potential recall bias. The unique Swedish Population Registers are highly complete; very little data are missing. For example, information regarding occupational status was almost 100% complete (99.2%). Furthermore, use of the national civic registration number in the database (removed and replaced with a serial number for the purpose of anonymity) made it possible to track each individual in different registers; for example, the migrant register, which allowed the calculation of exact risk time. Furthermore, we were able to account for the influence of geographical region, so that differing regional practice in hospitalization for dementia, Alzheimer's disease and AID was taken into consideration.
Hospitalizations for dementia, Alzheimer's disease, and other psychiatric and neurological conditions normally require a doctor's referral from the primary care service. Thus, each hospitalized patient is seen by at least two medical doctors. The doctor in the hospital is likely to be a neurologist. Dementia and Alzheimer's disease has not been validated in the Swedish registries. However, in Finland, another Nordic country, a validation study of dementia and Alzheimer's disease has been carried out. 18 The positive predictive value was high -96.3% and 100 for dementia and Alzheimer's disease, respectively. However, the sensitivity was lower -51% and 55.6%, respectively. As the overall positive predictive value in the Swedish registers is high (almost 90%), we therefore believe the positive predictive values for dementia and Alzheimer's disease in the Swedish registers are acceptable. 19 We believe the low sensitivity might lead to an underestimation of the estimated risks for dementia and Alzheimer's disease. With respect to autoimmune disorders, the overall diagnostic validity of the Swedish Inpatient Register is approximately 90%. 19 Validations of the discharge diagnosis of, for example, Crohn's disease and ulcerative colitis, show an overall validity close to 96% for these diagnoses. [20] [21] [22] [23] [24] The overall diagnostic accuracy in the Swedish Hospital Discharge Register has been referred to as being 88-90% on main diagnosis. 24 In the analysis, the patients were chosen according to their last hospitalization for an AID, it overcomes the problem of patients diagnosed with the first hospitalization may be several years after the onset of the condition. The highest risk for subsequent dementia and Alzheimer's disease after AID occurred during the first year (Table S2 ). The likely explanation is that these diseases presented synchronously with each other, or, these diseases were diagnosed during the treatment, presenting a lead-time bias in the results. However, the early detection of dementia and Alzheimer's disease was so uncommon that the SIR calculated for the whole follow-up period and for the whole period minus the first year (1+) were not essentially different. Furthermore, the lead-time bias only shifts the diagnoses earlier, and as the diagnostic accuracy is not compromised even the early cases are true dementia and Alzheimer's disease. Thus, the 1+ risk is an underestimate of the true risk. Complete hospital discharge information has been recorded in the Swedish hospital discharge register, suggesting that diagnostic misclassification should not have been the issue in the current study.
For specific AID, some of the observed associations have been reported earlier and our study provided further evidence for these associations. The increased risk for dementia and Alzheimer's disease was noted by Hashimoto's thyroiditis/hypothyroidism in a previous study 14 and has been suggested because of thyroid dysfunctions. Dementia and Alzheimer's disease has been found to be associated with type 1 diabetes 13 and systemic lupus erythematosus. 15 An increased prevalence rate of dementia and Alzheimer's disease has also been reported in patients with rheumatoid arthritis. 16 However, some of these cases of Alzheimer's disease were probably in excess because of the increased medical surveillance of patients with AID. Hence, Addison's disease, Crohn's disease, pemphigoid and rheumatoid arthritis were increased in "All" and not in "All 1+" periods. The effects of treatment (non-steroidal anti-inflammatory drugs and anti-tumor necrosis factor) might contribute to the identified associations. 16 The fact that the risk of dementia and Alzheimer's disease decreased over time might suggest that the dementia and Alzheimer's disease risk is linked to the inflammatory activity of the AID, which is likely to decrease over time due to treatment. In line with this hypothesis, several studies have suggested that disease activity is linked with immunoregulation. 25 Furthermore, the risk of dementia and Alzheimer's disease in AID patients was somewhat decreased over time, which might reflect a general decrease in dementia and Alzheimer's disease rates over time or progressively more intensive anti-inflammatory treatment regimes in recent decades. However, as we lack treatment data, we cannot test this hypothesis. The risks of dementia and Alzheimer's disease depended on the age, but the trends varied somewhat by AID types. When the hospitalization took place before the age 60 years, the SIR were particularly high; that is, 7.65 for multiple sclerosis, 7.23 for pernicious anemia, 5.38 for Sjögren's syndrome and 4.80 for Hashimoto's thyroiditis. It should be recommended that patients diagnosed before the age 60 years should undergo medical surveillance for early detection of autoimmune disorders. In contrast, lupoid hepatitis, multiple sclerosis and rheumatoid arthritis showed negative SIR in those hospitalized at ages >80 years, which might be indicative of the effect of immunoregulation 25 and treatment effect. 16 The present study had certain limitations. For example, we had no data on general dementia and Alzheimer's disease risk factors, such as smoking, because it would be unrealistic to gather such data for an entire national population. However, we did adjust for socioeconomic status, which is associated with factors, such as smoking. Adjustment was also made for six different comorbidities (chronic obstructive pulmonary disease, obesity, alcoholism and alcohol-related liver disease, hypertension, type 2 diabetes mellitus, and heart failure). Residual confounding might still be present, although we adjusted for comorbidities. Furthermore, incidence rates were calculated for the whole follow-up period, but also for different time-periods after diagnosis of AID. However, we do not know if the symptoms of dementia started earlier; that is, the actual onset might have occurred earlier.
In summary, the follow up of AID patients showed the increased patterns of subsequent dementia and Alzheimer's disease, which calls for continuous follow up of AID patients with individual information on the treatment.
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